Shares of Catalent, Inc. (CTLT) are rising more than 4% in the morning trade on Tuesday after reporting better-than-expected second-quarter results. The company also provided full-year revenue outlook, that came in above the Street view.
Net income for the second quarter increased to $93 million, or $0.52 per share, compared to $77 million, or $0.45 per share, in the same quarter a year ago.
Excluding one-time items, earnings were $163 million or $0.90 per share, that beat the average estimate of 12 analysts polled by Thomson Reuters at $0.83 per share.
Revenue for the quarter increased 34% year-over-year to $1.22 billion. The consensus estimate was for $1.15 billion.
Looking forward, the company has raised its full-year guidance to $4.74 billion - $4.86 billion from $4.62 billion - $4.82 billion. The consensus estimate stands at $4.71 billion.
Catalent provides delivery technologies, and makes solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products.
CTLT, currently at $108.84, has been trading in the range of $95.43- $142.64 in the last 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.